Array BioPharma spins off cardiovascular myopathy drug research into new subisidiary

Boulder drug development company Array BioPharma has spun off its research into a treatment for a rare degenerative heart disease into a separate company. Array BioPharma (Nasdaq: ARRAY), in a filing to the U.S. Securities& Exchange Commission on Chistmas Eve, revealed that it had contributed intellectual property, inventory, equipment, clinical trial data and other material about its experimental cardiomyopathy drug to a subsidiary it ’s calling Yarra Therapeutics. The oral drug, known only…
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Source Type: news